A detailed history of Lindbrook Capital, LLC transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 272 shares of FLGT stock, worth $5,475. This represents 0.0% of its overall portfolio holdings.

Number of Shares
272
Previous 347 21.61%
Holding current value
$5,475
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$19.6 - $25.06 $1,470 - $1,879
-75 Reduced 21.61%
272 $5,000
Q2 2024

Jul 31, 2024

BUY
$19.09 - $22.57 $4,467 - $5,281
234 Added 207.08%
347 $6,000
Q1 2024

Apr 25, 2024

BUY
$21.55 - $29.29 $1,293 - $1,757
60 Added 113.21%
113 $2,000
Q4 2023

Jan 31, 2024

BUY
$23.64 - $30.27 $1,252 - $1,604
53 New
53 $1,000
Q2 2023

Jul 28, 2023

SELL
$28.52 - $40.7 $827 - $1,180
-29 Reduced 78.38%
8 $0
Q1 2023

Apr 26, 2023

SELL
$29.39 - $36.27 $6,407 - $7,906
-218 Reduced 85.49%
37 $1,000
Q4 2022

Jan 24, 2023

SELL
$29.23 - $40.28 $4,676 - $6,444
-160 Reduced 38.55%
255 $0
Q3 2022

Nov 10, 2022

BUY
$37.92 - $63.74 $5,081 - $8,541
134 Added 47.69%
415 $16,000
Q2 2022

Aug 01, 2022

BUY
$47.98 - $62.75 $1,487 - $1,945
31 Added 12.4%
281 $15,000
Q1 2022

Apr 21, 2022

SELL
$49.85 - $96.11 $3,489 - $6,727
-70 Reduced 21.88%
250 $16,000
Q4 2021

Jan 18, 2022

SELL
$77.3 - $105.0 $2,319 - $3,150
-30 Reduced 8.57%
320 $32,000
Q3 2021

Nov 05, 2021

BUY
$74.87 - $110.87 $3,743 - $5,543
50 Added 16.67%
350 $31,000
Q1 2021

Apr 28, 2021

SELL
$59.3 - $183.85 $2,965 - $9,192
-50 Reduced 14.29%
300 $29,000
Q4 2020

Jan 27, 2021

BUY
$31.01 - $52.1 $1,550 - $2,605
50 Added 16.67%
350 $18,000
Q3 2020

Nov 03, 2020

BUY
$15.89 - $50.51 $4,767 - $15,153
300 New
300 $12,000

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $609M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.